Published on: Feb 28, 2017 at OncLive

Ramucirumab Beneficial in Advanced Gastric/GEJ Cancers Regardless of Age

By : OncLive

Regardless of age age, patients with advanced gastric or gastroesophageal juncture (GEJ) cancer saw a survival benefit when treated with the monoclonal antibody ramucirumab. See more from the summary at the 2017 Gastrointestinal Cancers Symposium in San Francisco.

Read More